Disease Domain | Count |
---|---|
Infectious Diseases | 4 |
Top 5 Drug Type | Count |
---|---|
Prophylactic vaccine | 2 |
Vaccine | 1 |
Monoclonal antibody | 1 |
Genetically engineered subunit vaccine | 1 |
Target |
Mechanism SARS-CoV-2 S protein inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. TW |
First Approval Date17 Jul 2021 |
Target- |
Mechanism Immunostimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. KR |
First Approval Date01 Apr 2016 |
Target- |
Mechanism Immunostimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date30 Jul 2022 |
Sponsor / Collaborator |
Start Date09 Jul 2022 |
Sponsor / Collaborator |
Start Date06 May 2022 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
MVC-COV1901 ( SARS-CoV-2 S protein ) | COVID-19 More | Approved |
H7N9 influenza vaccine(National Health Research Institutes) ( HER2 ) | Influenza, Human More | Phase 2 |
COVID-2019-quadrivalent seasonal influenza combined vaccine (Medigen Vaccine Biologics/Vaxess Technologies) | COVID-19 More | Preclinical |
WO2021228092 ( ACE2 ) | Virus Diseases More | Discovery |
Tetravalent dengue virus vaccine(Instituto Butantan) | Dengue More | Pending |